A Multidisciplinary Evaluation of Barriers to Enrolling Cancer Patients into Early Phase Clinical Trials: Challenges and Patient-centric Recommendations

References

• Califf R, Murray R, Rosenblatt M. Appendix DDiscussion Paper1: the clinical trials Enterprise in the United States: A call for disruptive innovation [Internet]. National Academies Press (U.S.); 2012 [ cited 2019 Feb 24]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK114657/
   Google Scholar
• Welton AJ, Vickers MR, Cooper JA, et al. Is recruitment more difficult with a placebo arm in randomised controlled trials? A quasirandomised, interview based study. BMJ. 1999;318:1114–1117.
   PubMed Web of Science ®Google Scholar
• Ng R Drugs: from discovery to approval [Internet]. 2015 [cited 2019 Feb 17]. Available from: http://public.eblib.com/choice/publicfullrecord.aspx?p=1895734.
   Google Scholar
• Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med. 2018;378:158–168.
   PubMed Web of Science ®Google Scholar
• English RA, Lebovitz Y, and Robert B. Giffin RB. Institute of medicine (US) Forum on Drug Discovery, Development, and Translation. Transforming clinical research in the United States: challenges and opportunities: workshop summary [Internet]. Washington (DC): National Academies Press (US); 2010 [ cited 2019 Feb 17]. Available fromhttp://www.ncbi.nlm.nih.gov/books/NBK50892/
   Google Scholar
• Horstmann E, McCabe MS, Grochow L, et al. Risks and benefits of phase 1 oncology trials, 1991 through 2002. N Engl J Med. 2005;352:895–904.
   PubMed Web of Science ®Google Scholar
• Workman P, Aboagye EO, Chung Y-L, et al. Minimally invasive pharmacokinetic and pharmacodynamic technologies in hypothesis-testing clinical trials of innovative therapies. J Natl Cancer Inst. 2006;98:580–598.
   PubMed Web of Science ®Google Scholar
• Ramirez AG, Chalela P, Suarez L, et al. Early phase clinical trials: referral barriers and promoters among physicians. J Community Med Health Educ [Internet]. 2012 [cited 2019 Feb 17];2. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3782313/.
   Google Scholar
• Mainous AG, Smith DW, Geesey ME, et al. Factors influencing physician referrals of patients to clinical trials. J Natl Med Assoc. 2008;100:1298–1303.
   PubMed Web of Science ®Google Scholar
• Ho J, Pond GR, Newman C, et al. Barriers in phase I cancer clinical trials referrals and enrollment: five-year experience at the Princess Margaret Hospital. BMC Cancer. 2006;6:263.
   PubMed Web of Science ®Google Scholar
• Severance HW. The research RVU (rRVU): in Search of a methodology to incentivize and compensate clinicians for participation in clinical research activities. Acad Med. 2016;91:10–19.
   PubMed Web of Science ®Google Scholar
• Jansen LA, Mahadevan D, Appelbaum PS, et al. Dispositional optimism and therapeutic expectations in early-phase oncology trials. Cancer. 2016;122:1238–1246.
   PubMed Web of Science ®Google Scholar
• Brody T. Clinical trials: study design, endpoints and biomarkers, drug safety, and FDA and ICH guidelines [Internet]. London: Academic; 2012 [ cited 2019 Feb 17]. Available from. http://www.clinicalkey.com/dura/browse/bookChapter/3-s2.0-C2011004245X
   Google Scholar
• ASHP guidelines on clinical drug research. American society of health-system pharmacists. Am J Health Syst Pharm. 1998;55:369–375.
   PubMed Web of Science ®Google Scholar
• Amin S, Avila J, Boron M, et al. HOPA investigational drug service best practice standards. 2014.
   Google Scholar
• Borad MJ, Curtis KK, Babiker HM, et al. The impact of concomitant medication use on patient eligibility for phase I cancer clinical trials. J Cancer. 2012;3:345–353.
   PubMed Web of Science ®Google Scholar
• Brown JN, Britnell SR, Stivers AP, et al. Medication safety in clinical trials: role of the pharmacist in optimizing practice, collaboration, and education to reduce errors. Yale J Biol Med. 2017;90:125–133.
   PubMed Web of Science ®Google Scholar
• You B, Pond G, Siu LL, et al. Heterogeneity among lists of cautioned or prohibited drugs in protocols of early-phase oncology trials. Ann Oncol. 2012;23:1633–1639.
   PubMed Web of Science ®Google Scholar
• Van Spall HGC, Toren A, Kiss A, et al. Eligibility criteria of randomized controlled trials published in high-impact general medical journals: a systematic sampling review. JAMA. 2007;297:1233–1240.
   PubMed Web of Science ®Google Scholar
• Wisinski KB, Cantu CA, Eickhoff J, et al. Potential cytochrome P-450 drug-drug interactions in adults with metastatic solid tumors and effect on eligibility for Phase I clinical trials. Am J Health Syst Pharm. 2015;72:958–965.
   PubMed Web of Science ®Google Scholar
• McGahey KE, Weiss GJ. Reviewing concomitant medications for participants in oncology clinical trials. Am J Health Syst Pharm. 2017;74:580–586.
   PubMed Web of Science ®Google Scholar
• McNeil C. NCI-MATCH launch highlights new trial design in precision-medicine era. J Natl Cancer Inst. 2015;107(7). DOI: https://doi.org/10.1093/jnci/djv193.
   Google Scholar
• Goodin S. Pharmacists’ critical role in cancer clinical trials. Am J Health Syst Pharm. 2018;75:592–593.
   PubMed Web of Science ®Google Scholar
• Fornasier G, Taborelli M, Francescon S, et al. Targeted therapies and adverse drug reactions in oncology: the role of clinical pharmacist in pharmacovigilance. Int J Clin Pharm. 2018;40:795–802.
   PubMed Web of Science ®Google Scholar
• Gaertner J, Elsner F, Pollmann-Dahmen K, et al. Electronic pain diary: a randomized crossover study. J Pain Symptom Manage. 2004;28:259–267.
   PubMed Web of Science ®Google Scholar
• Ness EA, Royce C. Clinical trials and the role of the oncology clinical trials nurse. Nurs Clin North Am. 2017;52:133–148.
   PubMed Web of Science ®Google Scholar
• Purdom MA, Petersen S, Haas BK. Results of an oncology clinical trial nurse role delineation study. Oncol Nurs Forum. 2017;44:589–595.
   PubMed Web of Science ®Google Scholar
• Matrana MR, Cook J. Building a Phase 1 cancer research program: lessons learned and progress made. Ochsner J. 2017;17:319–321.
   PubMed Web of Science ®Google Scholar
• Bevans M, Hastings C, Wehrlen L, et al. Defining clinical research nursing practice: results of a role delineation study. Clin Transl Sci. 2011;4:421–427.
   PubMed Web of Science ®Google Scholar
• Weber JS, Levit LA, Adamson PC, et al. American society of clinical oncology policy statement update: the critical role of phase I trials in cancer research and treatment. J Clin Oncol. 2015;33:278–284.
   PubMed Web of Science ®Google Scholar
• Massett HA, Mishkin G, Rubinstein L, et al. Challenges facing early phase trials sponsored by the National Cancer Institute: an analysis of corrective action plans to improve accrual. Clin Cancer Res. 2016;22:5408–5416.
   PubMed Web of Science ®Google Scholar
• Byrne M, Danielson N, Harris A, et al. Making inroads to the cure: barriers to clinical trial enrollment in hematopoietic cell transplantation. Clin Transplant. 2017;31(5).
   Web of Science ®Google Scholar
• Rule A, Glassock R The aging kidney. 2019.
   Google Scholar
• Mackay CB, Antonelli KR, Bruinooge SS, et al. Insurance denials for cancer clinical trial participation after the affordable care act mandate. Cancer. 2017;123:2893–2900.
   PubMed Web of Science ®Google Scholar
• 2015 Arizona revised statutes :: title 20 - Insurance :: § 20-2328 Accountable health plans; clinical trials; cancer; definitions [Internet]. Justia Law. [ cited 2019 Feb 18]. Available from: https://law.justia.com/codes/arizona/2015/title-20/section-20-2328/.
   Google Scholar
• Health insurance coverage of clinical trials [Internet]. Cancer.Net. 2014 [ cited 2019 Feb 18]. Available from: https://www.cancer.net/research-and-advocacy/clinical-trials/health-insurance-coverage-clinical-trials.
   Google Scholar
• Medicare C for, Baltimore MS 7500 SB, Usa M. Overview [Internet]. 2018 [ cited 2019 Jun 17]. Available from: https://www.cms.gov/Medicare/Coverage/ClinicalTrialPolicies/.
   Google Scholar
• Paying for clinical trials [Internet]. National Cancer Institute. 2011 [ cited 2019 Feb 18]. Available from: https://www.cancer.gov/about-cancer/treatment/clinical-trials/paying.
   Google Scholar
• Medicare C for, Baltimore MS 7500 SB, Usa M. Overview [Internet]. 2018 [ cited 2019 Feb 18]. Available from: https://www.cms.gov/Medicare/Coverage/ClinicalTrialPolicies/.
   Google Scholar
• Nipp RD, Lee H, Powell E, et al. Financial burden of cancer clinical trial participation and the impact of a cancer care equity program. Oncologist. 2016;21:467–474.
   PubMed Web of Science ®Google Scholar
• Bates SE, Berry DA, Balasubramaniam S, et al. Advancing clinical trials to streamline drug development. Clin Cancer Res. 2015;21:4527–4535.
   PubMed Web of Science ®Google Scholar
• Krishnankutty B, Bellary S, Kumar NBR, et al. Data management in clinical research: an overview. Indian J Pharmacol. 2012;44:168–172.
   PubMed Web of Science ®Google Scholar
• Kitterman DR, Cheng SK, Dilts DM, et al. The prevalence and economic impact of low-enrolling clinical studies at an academic medical center. Acad Med. 2011;86:1360–1366.
   PubMed Web of Science ®Google Scholar
• Fegan GW, Lang TA. Could an open-source clinical trial data-management system be what we have all been looking for? PLoS Med. 2008;5:e6.
   PubMed Web of Science ®Google Scholar
• fda approves imbruvica (ibrutinib) plus rituximab for patients with waldenström’s macroglobulinemia [Internet]. [ cited 2019 Mar 19]. Available from: https://www.drugs.com/newdrugs/fda-approves-imbruvica-ibrutinib-plus-rituximab-patients-waldenstr-m-s-macroglobulinemia-4812.html.
   Google Scholar
• Zupnick A The impact of faster drug approvals on oncology clinical trial design [Internet]. [ cited 2019 Mar 19]. Available from: http://www.appliedclinicaltrialsonline.com/impact-faster-drug-approvals-oncology-clinical-trial-design.
   Google Scholar